• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Hanger Reports First Quarter 2022 Financial Results

    5/4/22 4:05:00 PM ET
    $HNGR
    Medical Specialities
    Health Care
    Get the next $HNGR alert in real time by email

    Company Reports Strong Same Clinic Revenue Growth Trends; Reaffirms Guidance

    Hanger, Inc. (NYSE:HNGR), a leading provider of orthotic and prosthetic (O&P) patient care services and solutions, today announced its financial results for the first quarter ended March 31, 2022.

    Financial Highlights

    • Net revenues were $261.3 million for the three months ended March 31, 2022, compared to $237.5 million for the same period in 2021, reflecting growth of 10.0 percent. Patient Care same clinic revenue growth per day was 6.9 percent during the period with continuing increases in work-in-process levels during the quarter.
    • Net loss was $8.0 million for the three months ended March 31, 2022, compared to $3.3 million for the same period in 2021. Loss from operations was $2.5 million for the quarter compared to income from operations of $2.0 million for the same period in 2021.
    • Adjusted EBITDA was $8.9 million in the first quarter of 2022, compared to $13.5 million for the same period in 2021, reflecting a decline of $4.6 million. Comparative earnings in the period were affected by a favorable $3.5 million disallowance and patient non-payment rate in the prior year period, as well as other items specific to the current year period.
    • GAAP loss per share was $0.21 for the first quarter of 2022, compared to $0.09 per share for the same period in 2021. Adjusted loss per share was $0.15 for the three months ended March 31, 2022, compared to $0.08 for the same period in 2021.
    • The Company reaffirmed its full year guidance for 2022.

    Vinit Asar, President and Chief Executive Officer of Hanger, Inc., stated, "We are pleased with the strong rate of revenue growth achieved by our Patient Care business in the first quarter. We currently believe these positive growth trends will be sustainable as work-in-process levels have continued to increase during the quarter."

    Mr. Asar continued, "While we encountered some operational difficulties and increased costs during the period, we believe these effects were for the most part temporary in nature and specific to our first quarter results. Based on this, we remain comfortable with and have reaffirmed our guidance for the year."

    Segment Results for Three Months Ended March 31, 2022

    Patient Care Segment

    For the three months ended March 31, 2022, Patient Care net revenues were $219.8 million, an increase of $24.1 million, or 12.3 percent, compared to the same period in 2021. For the three month period, acquisitions of O&P clinics that were consummated in 2021 and 2022 contributed $11.2 million of incremental revenue.

    Net same clinic revenue on a day-adjusted basis grew 6.9 percent during the first quarter of 2022 compared to the same quarter in the prior year period. Patient Care results benefited from the continued improvement in patient volumes compared to the decreased levels of demand experienced due to the COVID pandemic during the same period in 2021.

    Excluding the effect of acquisitions, net revenue from prosthetics grew 7.7 percent and net revenue from orthotics grew 5.9 percent, each compared to the first quarter of 2021. Prosthetics comprised 52.1 percent of Patient Care segment net revenue for the quarter, compared to 51.7 percent in the same period of 2021. Income from operations in the Patient Care segment was $17.0 million during the first quarter of 2022, a decrease of $2.1 million compared to the $19.1 million reported in the prior year.

    Payor disallowances and patient non-payment were 4.4 percent of gross charges during the first quarter of 2022 which compared to 2.9 percent during the first quarter of 2021, resulting in an approximate $3.5 million comparative decrease to revenue, income from operations and Adjusted EBITDA. During the quarter, the Patient Care segment's income from operations and Adjusted EBITDA incurred $1.2 million and $0.9 million, respectively, in increased costs associated with its fabrication facilities, in part due to increased reliance on higher cost third party fabrication services related to constraints encountered in its own operations due to the effects of the Omicron variant of COVID-19, the availability of staffing and delays in the opening of its new fabrication facility in Phoenix, Arizona. That facility was successfully opened prior to the end of the quarter. The segment also incurred $0.6 million in increased freight costs as compared with the first quarter of 2021.

    Adjusted EBITDA for the segment was $23.1 million, which reflected a $1.9 million decrease compared to the first quarter of 2021. Adjusted EBITDA margin in the segment totaled 10.5 percent compared to 12.7 percent during the first quarter of 2021.

    Products & Services Segment

    For the three months ended March 31, 2022, Products & Services net revenues totaled $41.5 million, reflecting a decline of 0.8 percent compared with the same period in 2021. Revenue from the distribution of O&P componentry totaled $31.4 million, reflecting growth of $0.7 million, or 2.4 percent. Therapeutic solutions revenue in the first quarter totaled $10.1 million, a decline of $1.0 million, or 9.4 percent.

    Income from operations for the Products & Services segment was $2.5 million in the first quarter of 2022 compared to $4.7 million in the same period of 2021. Adjusted EBITDA for the segment totaled $4.9 million for the first quarter of 2022, a $2.0 million decline compared with the same period of 2021. Adjusted EBITDA margin in the segment totaled 11.7 percent compared to 16.4 percent during the first quarter of 2021.

    Corporate & Other

    Expenses associated with corporate and other activities increased by $0.3 million to $22.0 million for the quarter ended March 31, 2022 compared to the same period in 2021. Excluding the effect of depreciation and amortization, and acquisition-related expense, the net cost of corporate and other activities increased by $0.7 million to $19.0 million in the first quarter of 2022.

    Net Income; Interest Expense

    Interest expense totaled $7.4 million for the three month period ended March 31, 2022, which is unchanged from the prior year period.

    For the three month period ended March 31, 2022, net loss was $8.0 million compared with $3.3 million for the same period in 2021. GAAP diluted loss per share was $0.21 compared to $0.09 per share in 2021. Adjusted diluted loss per share was $0.15 for the three months ended March 31, 2022, compared to $0.08 per share for the same period in 2021.

    Net Cash Used In Operating Activities; Liquidity

    Cash flows used in operating activities for the three months ended March 31, 2022 were $8.3 million compared to cash flows used in operating activities of $42.4 million for the same period in 2021. The Company's days sales outstanding were 48 days as of March 31, 2022, which reflected a three-day increase as compared to the same period in 2021.

    On March 31, 2022, the Company had liquidity of $167.2 million, comprised of $37.4 million in cash and cash equivalents, and $129.8 million in available borrowing capacity under its revolving credit facility. This compares to total liquidity of $165.1 million on March 31, 2021.

    2022 Outlook

    Due in part to favorable same clinic growth trends, the previous incorporation of disallowance trends similar to those experienced in the first quarter and the anticipated temporary nature of certain other costs incurred in the quarter, the Company's outlook for 2022 remains unchanged since its initial announcement on February 7, 2022.

    As previously disclosed, the Company anticipates 2022 net revenue will be in a range between $1.190 billion and $1.220 billion, and Adjusted EBITDA in a range between $127 million and $132 million. The Company's outlook for 2022 includes approximately $35 million in revenue relating to the full year effect of acquisitions consummated in 2021.

    Adjusted EBITDA in this outlook is provided on a non-GAAP basis only because a reconciliation to the most comparable GAAP financial measure, net income, is not available without unreasonable effort due to the unpredictable nature of reconciling items that render such a reconciliation not meaningful for investors.

    Conference and Webcast Details

    Hanger's management team will host a conference call tomorrow, Thursday, May 5, 2022 at 8:30 a.m. Eastern time to discuss the Company's first quarter 2022 financial results and business outlook.

    To participate in the Company's live conference call, please dial (844) 200-6205 or +1 (929) 526-1599 for international participants and reference access code 335781. A live webcast, replay of the call, and earnings release will be available on the Company's Investor Relations website at https://investor.hanger.com/financial-reporting/quarterly-results. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call.

    Additional Notes

    A reconciliation of GAAP and non-GAAP financial results is included in the tables provided at the back of this press release. The Company has provided certain supplemental key statistics relating to its results for certain prior periods. These key statistics are non-GAAP measures used by the Company's management to analyze the Company's business results that are being provided for informational and analytical context.

    Accompanying supplemental information will be posted to the Investor Relations section of Hanger's web site at investor.hanger.com.

    About Hanger, Inc. – Headquartered in Austin, Texas, Hanger, Inc. (NYSE:HNGR) provides comprehensive, outcomes-based orthotic and prosthetic (O&P) services through its Patient Care segment, with approximately 875 Hanger Clinic locations nationwide. Through its Products & Services segment, Hanger distributes branded and private label O&P devices, products and components, and provides rehabilitative solutions. Recognized by Forbes as one of America's Best Employers for 2022, and rooted in 160 years of clinical excellence and innovation, Hanger is a purpose-driven company with a vision to lead the O&P markets by providing superior patient care, outcomes, services and value, aimed at empowering human potential. For more information on Hanger, visit investor.hanger.com.

    This earnings release contains statements that are forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include information concerning our liquidity and our possible or assumed future results of operations, including descriptions of our business strategies. These statements often include words such as "believe," "expect," "project," "potential," "anticipate," "intend," "plan," "estimate," "seek," "will," "may," "would," "should," "could," "forecasts" or similar words. These statements are based on certain assumptions that we have made in light of our experience in the industry as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate in these circumstances. We believe these assumptions are reasonable, but you should understand that these statements are not guarantees of performance or results, and our actual results could differ materially from those expressed in the forward-looking statements due to a variety of important factors, both positive and negative, that may be revised or supplemented in subsequent releases or reports. These statements involve risks, estimates, assumptions, and uncertainties that could cause actual results to differ materially from those expressed in these statements and elsewhere in this release. These uncertainties include, but are not limited to, the financial and business impacts of COVID-19 on our operations and the operations of our customers, suppliers, governmental and private payers and others in the healthcare industry and beyond; labor shortages and increased turnover in our employee base; contractual, inflationary and other general cost increases, including with regard to costs of labor, raw materials and freight; federal laws governing the health care industry; governmental policies affecting O&P operations, including with respect to reimbursement; failure to successfully implement a new enterprise resource planning system or other disruptions to information technology systems; the inability to successfully execute our acquisition strategy, including integration of recently acquired O&P clinics into our existing business; changes in the demand for our O&P products and services, including additional competition in the O&P services market; disruptions to our supply chain; our ability to enter into and derive benefits from managed-care contracts; our ability to successfully attract and retain qualified O&P clinicians; and other risks and uncertainties generally affecting the health care industry. For additional information and risk factors that could affect the Company, see its Form 10-K for the year ended December 31, 2021 and Quarterly Report on Form 10-Q for the three months ended March 31, 2022, each as filed with the Securities and Exchange Commission. The information contained in this press release is made only as of the date hereof, even if subsequently made available by the Company on its website or otherwise.

    Table 1

    Hanger, Inc.

    Condensed Consolidated Statements of Operations

    (Unaudited - in thousands, except share and per share amounts)

     

     

    For the Three Months Ended

    March 31,

     

     

     

    2022

     

     

     

    2021

     

    Net revenues

     

    $

    261,287

     

     

    $

    237,470

     

    Material costs

     

     

    85,592

     

     

     

    75,170

     

    Personnel costs

     

     

    101,675

     

     

     

    89,880

     

    Other operating costs

     

     

    36,168

     

     

     

    31,498

     

    General and administrative expenses

     

     

    32,442

     

     

     

    30,903

     

    Depreciation and amortization

     

     

    7,955

     

     

     

    7,998

     

    (Loss) income from operations

     

     

    (2,545

    )

     

     

    2,021

     

    Interest expense, net

     

     

    7,385

     

     

     

    7,340

     

    Non-service defined benefit plan expense

     

     

    160

     

     

     

    167

     

    Loss before income taxes

     

     

    (10,090

    )

     

     

    (5,486

    )

    Benefit for income taxes

     

     

    (2,113

    )

     

     

    (2,156

    )

    Net loss

     

    $

    (7,977

    )

     

    $

    (3,330

    )

     

     

     

     

     

    Basic and diluted per common share data:

     

     

     

     

    Basic and diluted loss per share

     

    $

    (0.21

    )

     

    $

    (0.09

    )

    Weighted average shares used to compute basic and diluted loss per share

     

     

    38,802,420

     

     

     

    38,268,332

     

    Table 2

    Hanger, Inc.

    Condensed Consolidated Balance Sheets

    (Unaudited - in thousands)

     

     

    As of March 31,

     

    As of December 31,

     

     

     

    2022

     

     

     

    2021

     

    ASSETS

     

     

     

     

    Current assets:

     

     

     

     

    Cash and cash equivalents

     

    $

    37,423

     

     

    $

    61,692

     

    Accounts receivable, net

     

     

    139,617

     

     

     

    152,058

     

    Inventories

     

     

    83,288

     

     

     

    87,462

     

    Income taxes receivable

     

     

    548

     

     

     

    581

     

    Other current assets

     

     

    18,527

     

     

     

    16,536

     

    Total current assets

     

     

    279,403

     

     

     

    318,329

     

    Non-current assets:

     

     

     

     

    Property, plant, and equipment, net

     

     

    80,906

     

     

     

    82,434

     

    Goodwill

     

     

    367,914

     

     

     

    363,554

     

    Other intangible assets, net

     

     

    25,032

     

     

     

    25,892

     

    Deferred income taxes

     

     

    45,743

     

     

     

    45,494

     

    Operating lease right-of-use assets

     

     

    141,820

     

     

     

    144,491

     

    Other assets

     

     

    18,844

     

     

     

    17,945

     

    Total assets

     

    $

    959,662

     

     

    $

    998,139

     

     

     

     

     

     

    TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

     

     

    Current liabilities:

     

     

     

     

    Current portion of long-term debt

     

    $

    13,535

     

     

    $

    14,938

     

    Accounts payable

     

     

    57,969

     

     

     

    63,565

     

    Accrued expenses and other current liabilities

     

     

    58,391

     

     

     

    60,399

     

    Accrued compensation related costs

     

     

    37,232

     

     

     

    54,465

     

    Current portion of operating lease liabilities

     

     

    33,182

     

     

     

    33,438

     

    Total current liabilities

     

     

    200,309

     

     

     

    226,805

     

     

     

     

     

     

    Long-term liabilities:

     

     

     

     

    Long-term debt, less current portion

     

     

    500,555

     

     

     

    502,307

     

    Operating lease liabilities

     

     

    121,725

     

     

     

    124,016

     

    Other liabilities

     

     

    28,520

     

     

     

    34,840

     

    Total liabilities

     

     

    851,109

     

     

     

    887,968

     

     

     

     

     

     

    Shareholders' equity:

     

     

     

     

    Common stock

     

     

    392

     

     

     

    389

     

    Additional paid-in capital

     

     

    373,092

     

     

     

    373,644

     

    Accumulated other comprehensive loss

     

     

    (4,242

    )

     

     

    (11,150

    )

    Accumulated deficit

     

     

    (259,993

    )

     

     

    (252,016

    )

    Treasury stock, at cost

     

     

    (696

    )

     

     

    (696

    )

    Total shareholders' equity

     

     

    108,553

     

     

     

    110,171

     

    Total liabilities and shareholders' equity

     

    $

    959,662

     

     

    $

    998,139

     

    Table 3

    Hanger, Inc.

    Condensed Consolidated Statements of Cash Flows

    (Unaudited - in thousands)

     

     

    For the Three Months Ended

    March 31,

     

     

     

    2022

     

     

     

    2021

     

    Cash flows used in operating activities:

     

     

     

     

    Net loss

     

    $

    (7,977

    )

     

    $

    (3,330

    )

    Adjustments to reconcile net loss to net cash used in operating activities:

     

     

     

     

    Depreciation and amortization

     

     

    7,955

     

     

     

    7,998

     

    Benefit from doubtful accounts

     

     

    (170

    )

     

     

    (211

    )

    Share-based compensation expense

     

     

    2,903

     

     

     

    3,179

     

    Deferred income taxes

     

     

    (2,466

    )

     

     

    (1,795

    )

    Amortization of debt discounts and issuance costs

     

     

    518

     

     

     

    472

     

    Gain on sale and disposal of fixed assets

     

     

    (228

    )

     

     

    (524

    )

    Changes in operating assets and liabilities, net of acquisitions:

     

     

     

     

    Accounts receivable, net

     

     

    12,845

     

     

     

    11,093

     

    Inventories

     

     

    4,259

     

     

     

    (1,437

    )

    Other current assets and other assets

     

     

    (2,540

    )

     

     

    (3,492

    )

    Income taxes

     

     

    33

     

     

     

    25

     

    Accounts payable

     

     

    (6,038

    )

     

     

    (14,055

    )

    Accrued expenses and other current liabilities

     

     

    1,328

     

     

     

    (1,299

    )

    Accrued compensation related costs

     

     

    (17,245

    )

     

     

    (36,936

    )

    Other liabilities

     

     

    (1,598

    )

     

     

    (1,576

    )

    Operating lease liabilities, net of amortization of right-of-use assets

     

     

    123

     

     

     

    (478

    )

    Net cash used in operating activities

     

     

    (8,298

    )

     

     

    (42,366

    )

    Cash flows used in investing activities:

     

     

     

     

    Acquisitions, net of cash acquired

     

     

    (4,001

    )

     

     

    (19,377

    )

    Purchase of property, plant, and equipment

     

     

    (4,003

    )

     

     

    (6,541

    )

    Purchase of therapeutic program equipment leased to third parties under operating leases

     

     

    (450

    )

     

     

    (395

    )

    Proceeds from sale of property, plant, and equipment

     

     

    551

     

     

     

    796

     

    Net cash used in investing activities

     

     

    (7,903

    )

     

     

    (25,517

    )

    Cash flows used in financing activities:

     

     

     

     

    Payment of employee taxes on share-based compensation

     

     

    (3,452

    )

     

     

    (4,520

    )

    Repayment of term loan

     

     

    (1,263

    )

     

     

    (1,263

    )

    Payment on Seller Notes

     

     

    (3,087

    )

     

     

    (446

    )

    Payments of financing lease obligations

     

     

    (266

    )

     

     

    (265

    )

    Payments under vendor financing arrangements

     

     

    —

     

     

     

    (275

    )

    Proceeds from the exercise of options

     

     

    —

     

     

     

    366

     

    Net cash used in financing activities

     

     

    (8,068

    )

     

     

    (6,403

    )

    Decrease in cash and cash equivalents

     

     

    (24,269

    )

     

     

    (74,286

    )

    Cash and cash equivalents at beginning of period

     

     

    61,692

     

     

     

    144,602

     

    Cash and cash equivalents at end of period

     

    $

    37,423

     

     

    $

    70,316

     

    Table 4

    Hanger, Inc.

    Segment Information: Revenue, EBITDA and Adjusted EBITDA

    (Unaudited - in thousands)

    EBITDA is defined as operating income before depreciation and amortization. Adjusted EBITDA is defined as EBITDA before certain charges, third-party professional fees in excess of normal amounts incurred in connection with our financial statement remediation, expenses associated with equity-based compensation, severance expenses, certain expenses incurred in connection with our acquisitions, proceeds received from grants under the Coronavirus Aid, Relief and Economy Security Act ("CARES Act") and certain other charges.

    We use EBITDA and Adjusted EBITDA as measures to assess the relative level of our indebtedness and our compliance with certain debt covenants which are based on these measures. Additionally, we utilize these measures to assess our operating and financial performance. We believe that these measures enhance a user's understanding of normal operating income excluding certain charges, depreciation and amortization.

    Neither EBITDA or Adjusted EBITDA are measures of financial performance computed in accordance with Generally Accepted Accounting Principles ("GAAP") and should not be considered in isolation nor as a substitute for operating income, net income, cash flows from operations, or other statement of operations or cash flow data prepared in conformity with GAAP, or as a measure of profitability or liquidity. In addition, the calculation of EBITDA and Adjusted EBITDA is susceptible to varying interpretations and calculations, and the amounts presented may not be comparable to similarly titled measures of other companies. EBITDA and Adjusted EBITDA may not be indicative of historical operating results, and we do not intend these measures to be predictive of future results of operations.

     

     

    For the Three Months Ended

    March 31,

     

     

     

    2022

     

     

     

    2021

     

     

     

     

     

     

    Net Revenue (a)

     

     

     

     

    Patient Care

     

    $

    219,818

     

     

    $

    195,682

     

    Products & Services

     

     

    41,469

     

     

     

    41,788

     

    Net revenue

     

    $

    261,287

     

     

    $

    237,470

     

     

     

     

     

     

    EBITDA (b)

     

     

     

     

    Patient Care

     

    $

    21,737

     

     

    $

    23,865

     

    Products & Services

     

     

    4,530

     

     

     

    6,611

     

    Corporate & Other

     

     

    (20,857

    )

     

     

    (20,457

    )

    EBITDA (Non-GAAP)

     

    $

    5,410

     

     

    $

    10,019

     

     

     

     

     

     

    Adjusted EBITDA (b)

     

     

     

     

    Patient Care

     

    $

    23,059

     

     

    $

    24,948

     

    Products & Services

     

     

    4,855

     

     

     

    6,870

     

    Corporate & Other

     

     

    (18,996

    )

     

     

    (18,274

    )

    Adjusted EBITDA (Non-GAAP)

     

    $

    8,918

     

     

    $

    13,544

     

     

     

     

     

     

    (a) Excludes intersegment revenue.

    (b) EBITDA and Adjusted EBITDA are "Non-GAAP" measures. Please refer to both Table 6 and Table 7 for a reconciliation of these measures to GAAP net income.

    Table 5

    Hanger, Inc.

    Reconciliation of Net Loss and Loss Per Share to

    Adjusted Net Loss and Adjusted Loss Per Share

    (Unaudited - in thousands, except share and per share amounts)

    Earnings Per Share (or "EPS") is defined as net income divided by our basic or diluted common shares during the applicable period. Adjusted EPS is defined as EPS adjusted for certain equity-based compensation charges, third-party professional fees in excess of normal amounts incurred in connection with our financial statement remediation, severance expenses, certain expenses incurred in connection with our acquisitions, proceeds received from grants under the CARES Act, and certain other charges.

    We utilize Adjusted EPS to assess our operating and financial performance. We believe that this measure enhances a user's understanding of normal operating results excluding certain charges.

    Adjusted EPS is not a measure of financial performance computed in accordance with GAAP and should not be considered in isolation nor as a substitute for operating income, net income, cash flows from operations, or other statement of operations or cash flow data prepared in conformity with GAAP, or as a measure of profitability or liquidity. In addition, the calculation of Adjusted EPS is susceptible to varying interpretations and calculations, and the amounts presented may not be comparable to similarly titled measures of other companies. Adjusted EPS may not be indicative of historical operating results, and we do not intend these measures to be predictive of future results of operations.

     

     

    For the Three Months Ended

    March 31,

     

     

     

    2022

     

     

     

    2021

     

     

     

     

     

     

    Net loss - as reported (GAAP)

     

    $

    (7,977

    )

     

    $

    (3,330

    )

     

     

     

     

     

    Adjustments:

     

     

     

     

    Amortization expense

     

     

    1,791

     

     

     

    1,234

     

    Acquisition-related expenses

     

     

    85

     

     

     

    160

     

    Hanger supply chain implementation costs

     

     

    386

     

     

     

    132

     

    Severance expenses

     

     

    134

     

     

     

    54

     

    Adjustments prior to tax effect

     

    $

    2,396

     

     

    $

    1,580

     

     

     

     

     

     

    Tax effect of specified adjustments (a)

     

     

    (266

    )

     

     

    (1,219

    )

    Adjustments after taxes

     

     

    2,130

     

     

     

    361

     

     

     

     

     

     

    Adjusted net loss (Non-GAAP)

     

    $

    (5,847

    )

     

    $

    (2,969

    )

     

     

     

     

     

    Basic and diluted loss per share - as reported (GAAP)

     

    $

    (0.21

    )

     

    $

    (0.09

    )

    Effect of above listed specified adjustments

     

     

    0.06

     

     

     

    0.01

     

    Adjusted basic and diluted loss per share - as reported (Non-GAAP)

     

    $

    (0.15

    )

     

    $

    (0.08

    )

     

     

     

     

     

    Shares used to compute basic and diluted loss per share

     

     

    38,802,420

     

     

     

    38,268,332

     

    (a) "Tax effect of specified adjustments" reflects the difference between the Company's effective provision for taxes and the application of a combined federal and state statutory tax rate of 24% for the 2022 and 2021 periods to the Company's earnings from operations before taxes, after the incorporation of the identified adjustments above.

    Table 6

    Hanger, Inc.

    Reconciliation of Net Loss to EBITDA and Adjusted EBITDA

    (Unaudited - in thousands)

    EBITDA is defined as operating income before depreciation and amortization. Adjusted EBITDA is defined as EBITDA before certain charges, third-party professional fees in excess of normal amounts incurred in connection with our financial statement remediation, expenses associated with equity-based compensation, severance expenses, certain expenses incurred in connection with our acquisitions, proceeds received from grants under the CARES Act and certain other charges.

    We use EBITDA and Adjusted EBITDA as measures to assess the relative level of our indebtedness and our compliance with certain debt covenants which are based on these measures. Additionally, we utilize these measures to assess our operating and financial performance. We believe that these measures enhance a user's understanding of normal operating income excluding certain charges, depreciation and amortization.

    Neither EBITDA or Adjusted EBITDA are measures of financial performance computed in accordance with Generally Accepted Accounting Principles ("GAAP") and should not be considered in isolation nor as a substitute for operating income, net income, cash flows from operations, or other statement of operations or cash flow data prepared in conformity with GAAP, or as a measure of profitability or liquidity. In addition, the calculation of EBITDA and Adjusted EBITDA is susceptible to varying interpretations and calculations, and the amounts presented may not be comparable to similarly titled measures of other companies. EBITDA and Adjusted EBITDA may not be indicative of historical operating results, and we do not intend these measures to be predictive of future results of operations.

     

     

    For the Three Months Ended

    March 31,

     

     

     

    2022

     

     

     

    2021

     

     

     

     

     

     

    Net loss - as reported (GAAP)

     

    $

    (7,977

    )

     

    $

    (3,330

    )

     

     

     

     

     

    Adjustments to calculate EBITDA:

     

     

     

     

    Depreciation and amortization

     

     

    7,955

     

     

     

    7,998

     

    Interest expense, net

     

     

    7,385

     

     

     

    7,340

     

    Non-service defined benefit plan expense

     

     

    160

     

     

     

    167

     

    Benefit for income taxes

     

     

    (2,113

    )

     

     

    (2,156

    )

    Adjustments - net loss to EBITDA

     

     

    13,387

     

     

     

    13,349

     

    EBITDA (Non-GAAP)

     

     

    5,410

     

     

     

    10,019

     

     

     

     

     

     

    Further adjustments to calculate Adjusted EBITDA:

     

     

     

     

    Equity-based compensation

     

     

    2,903

     

     

     

    3,179

     

    Acquisition-related expenses

     

     

    85

     

     

     

    160

     

    Hanger supply chain implementation costs

     

     

    386

     

     

     

    132

     

    Severance expenses

     

     

    134

     

     

     

    54

     

    Further adjustments - EBITDA to Adjusted EBITDA

     

     

    3,508

     

     

     

    3,525

     

    Adjusted EBITDA (Non-GAAP)

     

    $

    8,918

     

     

    $

    13,544

     

    Table 7

    Hanger, Inc.

    Segment Reconciliation of Income (Loss) From Operations to EBITDA and Adjusted EBITDA

    (Unaudited - in thousands)

    EBITDA is defined as operating income before depreciation and amortization. Adjusted EBITDA is defined as EBITDA before certain charges, third-party professional fees in excess of normal amounts incurred in connection with our financial statement remediation, expenses associated with equity-based compensation, severance expenses, certain expenses incurred in connection with our acquisitions, proceeds received from grants under the CARES Act and certain other charges.

    We use EBITDA and Adjusted EBITDA as measures to assess the relative level of our indebtedness and our compliance with certain debt covenants which are based on these measures. Additionally, we utilize these measures to assess our operating and financial performance. We believe that these measures enhance a user's understanding of normal operating income excluding certain charges, depreciation and amortization.

    Neither EBITDA or Adjusted EBITDA are measures of financial performance computed in accordance with Generally Accepted Accounting Principles ("GAAP") and should not be considered in isolation nor as a substitute for operating income, net income, cash flows from operations, or other statement of operations or cash flow data prepared in conformity with GAAP, or as a measure of profitability or liquidity. In addition, the calculation of EBITDA and Adjusted EBITDA is susceptible to varying interpretations and calculations, and the amounts presented may not be comparable to similarly titled measures of other companies. EBITDA and Adjusted EBITDA may not be indicative of historical operating results, and we do not intend these measures to be predictive of future results of operations.

     

     

    For the Three Months Ended

    March 31,

     

     

     

    2022

     

     

     

    2021

     

    Patient Care

     

     

     

     

    Income from operations - as reported (GAAP)

     

    $

    16,993

     

     

    $

    19,050

     

    Depreciation & amortization

     

     

    4,744

     

     

     

    4,815

     

    EBITDA (Non-GAAP)

     

     

    21,737

     

     

     

    23,865

     

    Further adjustments to calculate Adjusted EBITDA:

     

     

     

     

    Equity-based compensation

     

     

    831

     

     

     

    897

     

    Hanger supply chain implementation costs

     

     

    470

     

     

     

    132

     

    Severance expenses

     

     

    21

     

     

     

    54

     

    Further adjustments - EBITDA to Adjusted EBITDA

     

     

    1,322

     

     

     

    1,083

     

    Adjusted EBITDA (Non-GAAP)

     

     

    23,059

     

     

     

    24,948

     

     

     

     

     

     

    Products & Services

     

     

     

     

    Income from operations - as reported (GAAP)

     

     

    2,507

     

     

     

    4,676

     

    Depreciation & amortization

     

     

    2,023

     

     

     

    1,935

     

    EBITDA (Non-GAAP)

     

     

    4,530

     

     

     

    6,611

     

    Further adjustments to calculate Adjusted EBITDA:

     

     

     

     

    Equity-based compensation

     

     

    296

     

     

     

    259

     

    Hanger supply chain implementation costs

     

     

    (84

    )

     

     

    —

     

    Severance expenses

     

     

    113

     

     

     

    —

     

    Further adjustments - EBITDA to Adjusted EBITDA

     

     

    325

     

     

     

    259

     

    Adjusted EBITDA (Non-GAAP)

     

     

    4,855

     

     

     

    6,870

     

     

     

     

     

     

    Corporate & Other

     

     

     

     

    Loss from operations - as reported (GAAP)

     

     

    (22,045

    )

     

     

    (21,705

    )

    Depreciation & amortization

     

     

    1,188

     

     

     

    1,248

     

    EBITDA (Non-GAAP)

     

     

    (20,857

    )

     

     

    (20,457

    )

    Further adjustments to calculate Adjusted EBITDA:

     

     

     

     

    Equity-based compensation

     

     

    1,776

     

     

     

    2,023

     

    Acquisition related expenses

     

     

    85

     

     

     

    160

     

    Further adjustments - EBITDA to Adjusted EBITDA

     

     

    1,861

     

     

     

    2,183

     

    Adjusted EBITDA (Non-GAAP)

     

     

    (18,996

    )

     

     

    (18,274

    )

    Total Adjusted EBITDA (Non-GAAP)

     

    $

    8,918

     

     

    $

    13,544

     

    Table 8

    Hanger, Inc.

    Indebtedness

    (Unaudited - in thousands)

     

     

    As of March 31,

     

    As of December 31,

     

     

     

    2022

     

     

     

    2021

     

    Debt:

     

     

     

     

    Term Loan B

     

    $

    484,800

     

     

    $

    486,063

     

    Seller Notes

     

     

    27,725

     

     

     

    29,812

     

    Deferred payment obligation

     

     

    4,000

     

     

     

    4,000

     

    Finance lease liabilities and other

     

     

    3,097

     

     

     

    3,344

     

    Total debt before unamortized discount and debt issuance costs

     

     

    519,622

     

     

     

    523,219

     

    Unamortized discount and debt issuance costs, net

     

     

    (5,532

    )

     

     

    (5,974

    )

    Total debt

     

    $

    514,090

     

     

    $

    517,245

     

     

     

     

     

     

    Current portion of long-term debt:

     

     

     

     

    Term Loan B

     

    $

    5,050

     

     

    $

    5,050

     

    Seller Notes

     

     

    7,595

     

     

     

    8,969

     

    Finance lease liabilities and other

     

     

    890

     

     

     

    919

     

    Total current portion of long-term debt

     

     

    13,535

     

     

     

    14,938

     

    Long-term debt

     

    $

    500,555

     

     

    $

    502,307

     

     

     

     

     

     

    Net indebtedness:

     

     

     

     

    Total debt before unamortized discount and debt issuance costs

     

    $

    519,622

     

     

    $

    523,219

     

    Cash and cash equivalents

     

     

    (37,423

    )

     

     

    (61,692

    )

    Net indebtedness

     

    $

    482,199

     

     

    $

    461,527

     

    Table 9

    Hanger, Inc.

    Key Operating Metrics

     

     

    As of and For the Three Months Ended March 31,

     

     

    2022

     

    2021

     

     

     

     

     

    Same clinic revenue (a):

     

     

     

     

    Growth (decline) rate prior to disallowances and PNP

     

    7.9

    %

     

    (1.1

    )%

    Growth rate on net revenue

     

    6.9

    %

     

    1.4

    %

     

     

     

     

     

    Clinical locations:

     

     

     

     

    Patient care clinics

     

    757

     

     

    718

     

    Satellite clinics

     

    118

     

     

    107

     

    Total clinical locations

     

    875

     

     

    825

     

    (a) Same Clinic Revenue is computed on a per day basis. This normalizes revenue for the number of days a clinic was open in each comparable period. These measures are both non-GAAP and unaudited.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220504006015/en/

    Get the next $HNGR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HNGR

    DatePrice TargetRatingAnalyst
    7/25/2022$24.00 → $18.75Buy → Hold
    Jefferies
    More analyst ratings

    $HNGR
    Leadership Updates

    Live Leadership Updates

    See more
    • Evolent Health Appoints Seth R. Frank as Vice President, Investor Relations

      WASHINGTON, Dec. 1, 2021 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent"), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced that Seth R. Frank has joined the company as Vice President, Investor Relations, effective immediately. Reporting to John Johnson, Evolent's Chief Financial Officer, Seth will lead Evolent's investor relations (IR) strategy and oversee its relationships with the investment community. "Seth provides a demonstrated track record of proactive, finance-driven leadership in health care investor relations to Evolent," said Evolent Health Chief Financial Officer John Johnson. "He brings long-ter

      12/1/21 8:00:00 AM ET
      $EVH
      $HNGR
      $MDRX
      Other Consumer Services
      Consumer Discretionary
      Medical Specialities
      Health Care

    $HNGR
    Financials

    Live finance-specific insights

    See more

    $HNGR
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $HNGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $HNGR
    SEC Filings

    See more

    $HNGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Hanger Reports Second Quarter 2022 Financial Results

      Hanger, Inc. (NYSE:HNGR), a leading provider of orthotic and prosthetic (O&P) patient care services and solutions, today announced its financial results for the second quarter and six months ended June 30, 2022. Financial Highlights Net revenues were $312.0 million for the three months ended June 30, 2022, compared to $280.8 million for the same period in 2021, reflecting growth of 11.1 percent. Patient Care same clinic revenue growth per day was 6.2 percent during the period. Net income was $10.1 million for the three months ended June 30, 2022, compared to $10.2 million for the same period in 2021. Income from operations was $20.8 million for the quarter compared to $20.1 million for

      8/8/22 4:05:00 PM ET
      $HNGR
      Medical Specialities
      Health Care
    • Hanger, Inc. Announces Definitive Agreement to be Acquired by Patient Square Capital for $18.75 Per Share in Cash

      Total Enterprise Value of Approximately $1.25 Billion Hanger, Inc. (NYSE:HNGR), a leading provider of orthotic and prosthetic (O&P) patient care services and solutions, announced today that it has entered into a definitive agreement to be acquired by Patient Square Capital, a dedicated health care investment firm. Under the terms of the agreement, which has been unanimously approved by Hanger's Board of Directors, Hanger stockholders will receive $18.75 in cash per share, representing an approximately 29% premium to the 30 calendar day volume-weighted average price (VWAP) ending July 20, 2022, and a total enterprise value of approximately $1.25 billion. Upon completion of the transaction,

      7/21/22 4:13:00 PM ET
      $HNGR
      Medical Specialities
      Health Care
    • Hanger Announces Date of 2022 Second Quarter Earnings Release and Conference Call

      Hanger, Inc. (NYSE:HNGR), a leading provider of orthotic and prosthetic (O&P) patient care services and solutions, announced it will report its financial results for the second quarter and six months ended June 30, 2022 after the stock market closes on Monday, August 8, 2022. Hanger's management team will host a conference call to discuss the second quarter 2022 financial results the following morning on Tuesday, August 9, 2022 at 8:30 a.m. Eastern time. To participate in the Company's live conference call, please dial (844) 200-6205 or +1 (929) 526-1599 for international participants and reference access code 020458. A live webcast, replay of the call and earnings release, will be availa

      7/7/22 8:00:00 AM ET
      $HNGR
      Medical Specialities
      Health Care
    • Hanger, Inc. Completes Acquisition by Patient Square Capital

      Hanger, Inc. (NYSE:HNGR), a leading provider of orthotic and prosthetic (O&P) patient care services and solutions, today announced the completion of its previously announced transaction to be acquired by Patient Square Capital, a leading dedicated health care investment firm, in an all-cash transaction. The acquisition was previously announced on July 21, 2022, and Hanger's stockholders approved the transaction at a Special Meeting of Stockholders held on September 30, 2022. As a result of the completion of the acquisition, Hanger stockholders will receive $18.75 in cash per share of common stock, and Hanger's common stock will no longer be traded on the New York Stock Exchange (NYSE). Wit

      10/3/22 12:30:00 PM ET
      $HNGR
      Medical Specialities
      Health Care
    • Hanger, Inc. Stockholders Approve Acquisition by Patient Square Capital

      Hanger, Inc. (NYSE:HNGR), a leading provider of orthotic and prosthetic (O&P) patient care services and solutions, today announced that its stockholders approved at a special meeting the acquisition of Hanger by Patient Square Capital, a leading dedicated health care investment firm. Vinit Asar, Hanger's President and Chief Executive Officer said, "I would like to express my gratitude to the Hanger stockholders for their support today, and throughout this transaction process. The Hanger team is excited about this partnership with Patient Square Capital, and beginning our next chapter as a private company. We believe this collaboration will enable us to accelerate our growth and enhance our

      9/30/22 4:05:00 PM ET
      $HNGR
      Medical Specialities
      Health Care
    • Frontier Communications Set to Join S&P MidCap 400; Hain Celestial Group to Join S&P SmallCap 600

      NEW YORK, Sept. 27, 2022 /PRNewswire/ -- Frontier Communications Parent Inc. (NASD: FYBR) will replace The Hain Celestial Group Inc. (NASD:HAIN) in the S&P Midcap 400 and The Hain Celestial Group will replace Hanger Inc. (NYSE:HNGR) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, October 3. Patient Square Capital, LP. is acquiring Hanger in a deal expected to be completed soon pending final closing conditions. The Hain Celestial Group is more representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Se

      9/27/22 6:16:00 PM ET
      $FYBR
      $HAIN
      $HNGR
      $SPGI
      Telecommunications Equipment
      Telecommunications
      Packaged Foods
      Consumer Staples
    • SEC Form 4: Sullivan Kathryn M returned $1,162,988 worth of shares to the company (62,026 units at $18.75), closing all direct ownership in the company

      4 - HANGER, INC. (0000722723) (Issuer)

      10/4/22 5:25:47 PM ET
      $HNGR
      Medical Specialities
      Health Care
    • SEC Form 4: Jones Mark M returned $386,138 worth of shares to the company (20,594 units at $18.75), closing all direct ownership in the company

      4 - HANGER, INC. (0000722723) (Issuer)

      10/4/22 5:21:56 PM ET
      $HNGR
      Medical Specialities
      Health Care
    • SEC Form 4: Pettingill Richard returned $1,465,031 worth of shares to the company (78,135 units at $18.75), closing all direct ownership in the company

      4 - HANGER, INC. (0000722723) (Issuer)

      10/4/22 5:21:57 PM ET
      $HNGR
      Medical Specialities
      Health Care
    • SEC Form 15-12G filed by Hanger Inc.

      15-12G - HANGER, INC. (0000722723) (Filer)

      10/13/22 9:00:25 AM ET
      $HNGR
      Medical Specialities
      Health Care
    • SEC Form EFFECT filed by Hanger Inc.

      EFFECT - HANGER, INC. (0000722723) (Filer)

      10/7/22 12:15:11 AM ET
      $HNGR
      Medical Specialities
      Health Care
    • SEC Form S-8 POS filed by Hanger Inc.

      S-8 POS - HANGER, INC. (0000722723) (Filer)

      10/3/22 1:29:11 PM ET
      $HNGR
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Hanger Inc. (Amendment)

      SC 13G/A - HANGER, INC. (0000722723) (Subject)

      11/8/22 11:20:47 AM ET
      $HNGR
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Hanger Inc. (Amendment)

      SC 13G/A - HANGER, INC. (0000722723) (Subject)

      8/10/22 2:56:04 PM ET
      $HNGR
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Hanger Inc. (Amendment)

      SC 13G/A - HANGER, INC. (0000722723) (Subject)

      8/8/22 10:36:46 AM ET
      $HNGR
      Medical Specialities
      Health Care

    $HNGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Hanger downgraded by Jefferies with a new price target

      Jefferies downgraded Hanger from Buy to Hold and set a new price target of $18.75 from $24.00 previously

      7/25/22 7:27:44 AM ET
      $HNGR
      Medical Specialities
      Health Care